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Background: Second primary cancers (SPCs) are important clinically as they may nega-
tively influence patient survival and they may tell about therapeutic side effects and general 
causes of cancer. Population-based literature concerning SPCs after hepatobiliary cancers is 
limited and here we assess risks of SPCs after hepatocellular cancer (HCC), and cancers of 
the gallbladder, bile ducts and ampulla of Vater. In reverse order, we consider the risk of 
hepatobiliary cancers as SPCs after any cancer.
Methods: We used standardized incidence ratios (SIRs) to estimate bidirectional relative 
risks of subsequent cancers associated with hepatobiliary cancers. Cancer diagnoses were 
obtained from the Swedish Cancer Registry from years 1990 through 2015.
Results: We identified 9997 primary HCCs, 1365 gallbladder cancers and 4721 bile duct 
cancers. After HCC, risks of four SPCs were increased: gallbladder (SIR = 4.38; 95% 
confidence interval 1.87–8.67), thyroid (4.13; 1.30–9.70), kidney (2.92; 1.66–4.47) and 
squamous cell skin (1.55; 1.02–2.26) cancers. In reverse order, HCC as SPC, in addition 
to the above cancers, associations included upper aerodigestive tract, esophageal, small 
intestinal and bladder cancers and non-Hodgkin lymphoma. For gallbladder and bile duct 
cancers, associations were found with small intestinal and pancreatic cancers.
Conclusion: The results suggested that HCC is associated with two types of SPC, one 
related to shared environmental risk factors, such as alcohol, exemplified by upper aero-
digestive tract and esophageal cancer, and the other related to immune dysfunction, exem-
plified by squamous cell skin cancer. SPCs associated with gallbladder and bile duct cancers 
suggest predisposition to mutations in the mismatch repair gene MLH1.
Keywords: cancer incidence, relative risk, second primary cancer, cancer etiology, 
hepatobiliary cancer
Introduction
Primary hepatobiliary cancers include hepatocellular carcinoma (HCC), gallbladder 
cancer and cancers of the extrahepatic (and intrahepatic) bile ducts (biliary tract) and of 
the ampulla of Vater.1,2 The incidence of these cancers show large international 
variation, which correlates with the known risk factors that are best characterized for 
HCC: chronic infection by hepatitis B or C virus, cholangiocarcinogenic liver flukes, 
ingestion of aflatoxin B1 mycotoxin, non-alcoholic metabolic liver disease, alcohol- 
induced or other types of liver cirrhosis and smoking.1,3–7 The international variation in 
incidence is less dramatic for gallbladder cancer, for which gallstones, carcinogen 
exposure, Salmonella enterica serovar Typhi and Helicobacter pylori infection and 
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biliary cysts and other structural abnormalities are known 
risk factors.1,8,9 For female gallbladder cancer, obesity is 
a strong risk factor, which is also associated with 
gallstones.10 In addition to environmental risk factors, 
increased familial risk suggests a role for genetic factors in 
these cancers.11 Familial aggregation of HCC has been 
observed in high-risk areas and chronic hepatitis B carriers, 
but to what extent the results show shared environment or 
inherited susceptibility remains unknown.12,13 HCC is 
a manifestation in some rare inherited metabolic diseases, 
such as porphyria cutanea tarda and inherited 
hemochromatosis.1 All hepatobiliary cancers are increased 
in autoimmune disease patients thus indicating the contribu-
tion of immune dysfunction in their etiology; the highest 
risks were found after primary biliary cirrhosis and autoim-
mune hepatitis.14,15 Biliary tract and gallbladder cancers 
manifest in hereditary nonpolyposis colorectal cancer 
(HNPCC, Lynch syndrome), particularly in mutation carriers 
of the gene MLH1.16 Northern Europe is a low-risk area for 
hepatobiliary cancers, which is also confirmed in cancer risks 
of the local immigrants.17 The age-standardized incidence 
for HCC in 2008 for Sweden was estimated at 4.6/100,000 
for men and 2.0/100,000 for women while the rates for 
gallbladder cancer were 1.8 and 2.9/100,000, respectively.18 
The incidence of bile duct and ampulla Vater cancers were 
each about half of the rates for gallbladder cancer.11 Survival 
in all these cancers is generally poor.18
Second primary cancers (SPCs) are an increasing type 
of cancer because overall survival in cancer is increasing 
and the likelihood of being diagnosed with another cancer 
is thus increasing.19 Consequently, in cancers of poor 
survival, SPCs are less common and also reporting of 
SPCs may not be complete because of the concerns 
about the first primary cancer (FPC).20 Population-based 
literature on SPCs after hepatobiliary cancers is not exten-
sive, probably because of the poor survival. The relative 
risk of SPCs after HCC is low but in those surviving at 
least two years, an increase was found for second stomach, 
biliary tract, bladder and kidney cancers.20,21 We have 
noted that the risk for HCC was increased when diagnosed 
as SPC after FPC compared to the risks of SPCs following 
HCC.22,23 We decided therefore to examine systematically 
and bidirectionally the risks of any cancer after hepatobili-
ary cancers and of hepatobiliary cancers as SPC after any 
cancer. The hepatobiliary cancers considered were HCC 
and cancers of the gallbladder, bile ducts and ampulla of 
Vater, identified from the nationwide Swedish Cancer 
Registry.
Materials and Methods
We used nationwide data in this paper derived from 
Statistics Sweden and the Swedish Cancer Register. Data 
were delivered to us in a pseudonymized format. We have 
no access to any keys between the pseudonymized data 
delivered to us and personal information, such as name, 
address, or personal ID numbers. The International 
Classification of Diseases revision 7 (ICD-7 and later 
revisions) distinguishes four groups of primary liver and 
biliary tract tumors by organ sites under code 155: liver 
(ICD-7 code 155.0), gallbladder (155.1), bile ducts (155.2 
through 155.9) and ampulla of Vater (155.3) as part of bile 
ducts. These and other cancer data were retrieved from the 
Swedish Cancer Registry covering years 1990 through 
2015. The other cancers include any of 23 common male 
and 24 female FPCs or SPCs. Patients were followed up 
from 1990 onward from the diagnosis of FPC until the end 
of 2015 or diagnosis of SPC, immigration or death, which-
ever came earliest. Only discordant (different) FPC-SPC 
pairs were included. Upper aerodigestive tract (UAT) 
included lip, oral cavity, pharynx and larynx. Kidney can-
cer only included renal cell carcinoma, though renal pelvic 
and ureteral cancers were considered. However, case num-
bers were few and not reported. For skin cancer, only 
melanoma and squamous cell carcinoma were included.
Standardized incidence ratios (SIRs) for SPC were 
estimated through the observed number of SPCs divided 
by the expected number of cases. The expected number of 
cancer cases was estimated by the followed person-years 
after first primary cancer diagnosis, multiplied by the 
incidence of the same cancer as FPC in the general popu-
lation. The estimation was done for both sexes combined 
or separately, and adjusted for age, calendar year, place of 
residence and socioeconomic factors. The 95% confidence 
interval (95% CI) for SIRs were calculated by assuming 
the Poisson distribution. The data analysis for this paper 
was generated using SAS software, Version 9.4 of the SAS 
System for Windows. Copyright © 2016 SAS Institute 
Inc., Cary, NC, USA.
In interpreting the findings, we try to emphasize their 
clinical importance by considering the magnitude of the 
risk estimate and its precision, ie, the width of CI.24 
According to this convention, we do not refer to “statis-
tical significance” when CI does not contain the null value. 
However, as the study includes close to 500 SIRs we help 
the reader to focus on the results with potential clinical 
importance by bolding SIRs when the 95% CIs do not 
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overlap with 1.00. To simplify the tables, cancer sites were 
not reported if less than five cases were found in Table 1 
column “HCC as SPC”; however, all hepatobiliary sites 
were kept. The total numbers “All” included also the 
deleted sites.
Results
Characteristics of the study population are described in 
Table 1. During the follow-up period of 1990 to 2015, 
we identified 9997 HCC, 64.9% male, median diagnostic 
age 71 years (inter quartile range IQR, 62–78), 5277 
gallbladder cancers 25.9% male, median diagnostic age 
73 years (IQR,65–80) and 4721 bile duct cancers 47.7% 
male, median diagnostic age 72 years (IQR,64–80). 
Among bile duct cancers, 1025 Ampulla of Vater cancers 
(56.2% male) were identified and the median diagnostic 
age was 72 years (IQR, 63–79). The total number of other 
cancers considered was 1,056,493 (52.0% male). The 
median follow-up time was three (0–11) months for SPC 
after HCC, three (1–10) months after gallbladder and five 
(1–15) months after bile duct cancer. For hepatobiliary 
cancers as SPC, the corresponding times were 37 (9–97) 
months for HCC, 36 (9–96) months for gallbladder and 36 
(9–96) months for bile duct cancer.
SIRs for SPCs of both sexes associated with HCC are 
shown in Table 2. Based on 297 cases, the overall risk for 
SPCs after HCC was not increased (SIR 1.04). Risks for 
four SPCs were increased: gallbladder (4.38), thyroid 
(4.13), kidney (2.92) and skin squamous cell (SCC, 1.55) 
cancers. In reverse order, HCC as SPC, the overall SIR was 
increased to 1.19 with 1012 cases. Risks for gallbladder 
(2.88), kidney (2.14) and skin SCC (1.45) were bidirection-
ally increased, as was thyroid cancer at borderline (2.13). 
Additional SIRs were increased for UAT, esophageal, small 
intestinal and bladder cancers and NHL. For kidney cancer, 
results were assessed separately for right and left kidney 
(the right kidney is located in the backside of the liver) but 
the case numbers were too small to be conclusive. In this 
and subsequent tables, some associations with breast and 
prostate cancers were decreased. Sex-specific data are 
shown in Supplementary Tables 1 and 2. Male data of 
HCC with many more cases drove the results.
Similar analysis is shown for gallbladder cancer in 
Table 3. Only risks for HCC (2.88), bile duct (5.05) and 
kidney (3.04) cancers were increased as SPCs. In reverse 
Table 1 Characteristics of the Cancer Patients Included in the Study
Characteristics Hepatocellular Carcinoma Gallbladder Cancer Bile Duct Cancer Other Cancers
Median Age at Diagnosis (IQR) 71 (62–78) 73 (65–80) 72 (64–80) 69 (59–78)
N % N % N % N %
Year of diagnosis 1990–1995 2285 22.9 1883 35.7 1176 24.9 213,842 20.1
1996–2000 1698 17.0 1100 20.9 896 19.0 187,159 17.6
2001–2005 1717 17.2 858 16.3 823 17.4 205,822 19.4
2006–2010 1806 18.1 715 13.6 817 17.3 218,218 20.5
2011–2015 2491 24.9 721 13.7 1009 21.4 238,755 22.4
Gender Male 6485 64.9 1365 25.9 2252 47.7 553,389 52.0
Female 3512 35.1 3912 74.1 2469 52.3 510,407 48.0
Place of residence Big cities 4736 47.4 1973 37.4 2127 45.1 496,423 46.7
South Sweden 3019 30.2 2151 40.8 1677 35.5 363,923 34.2
North Sweden 2185 21.9 1146 21.7 910 19.3 200,655 18.9
Unspecified 57 0.6 7 0.1 7 0.2 2795 0.3
Socioeconomic status Agriculture 64 0.6 49 0.9 58 1.2 43,524 1.3
Private 348 3.5 117 2.2 157 3.3 66,090 3.4
Professional 502 5.0 213 4.0 263 5.6 103,703 7.5
Blue collar 1376 13.8 688 13.0 769 16.3 339,808 19.9
Worker 2138 21.4 1035 19.6 1005 21.3 442,109 22.7
Other 5569 55.7 3175 60.2 2469 52.3 68,562 45.3
All 9997 100 5277 100 4721 100 1,063,796 100
Abbreviation: IQR, inter quartile range.
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order, gallbladder cancer as SPC, associations were found for 
small intestinal cancer (3.64) and HCC (4.38). Sex-specific 
results are shown in Supplementary Tables 1 and 2.
Table 4 shows results for bile duct cancer. The SIR for 
pancreatic cancer was increased to 2.80 as SPC. In the 
reverse order, risk of bile duct cancer was increased after 
small intestinal (3.73) and gallbladder (5.05) cancers. Sex- 
specific data showed that the results were driven by male 
data, as no significant associations were noted for women 
(Supplementary Tables 1 and 2). Risks of both small 
intestinal and pancreatic cancers were bidirectionally 
increased in men; small intestinal cancer as SPC, SIR 
6.51 and in reverse order SIR 5.94; pancreas cancer as 
SPC, SIR 3.07 and in reverse order SIR 3.18.
Table 2 Risks of SPCs After Hepatocellular Carcinoma (HCC) and Those of HCC as SPCs
Cancer Site SPC After HCC HCC as SPC
N SIR 95% CI N SIR 95% CI
UAT 8 1.19 0.51 2.36 40 2.13 1.52 2.91
Esophagus 3 0.82 0.15 2.43 11 2.43 1.21 4.36
Stomach 7 0.76 0.30 1.58 18 1.22 0.72 1.93
Small intestine 3 2.12 0.40 6.28 10 3.01 1.44 5.56
CRC 38 0.99 0.70 1.36 117 1.15 0.95 1.38
Gallbladder 8 4.38 1.87 8.67 6 2.88 1.04 6.31
Bile ducts 2 1.13 0.11 4.16 4 1.84 0.48 4.77
Pancreas 14 1.58 0.86 2.65 7 0.84 0.33 1.75
Lung 27 0.94 0.62 1.36 44 1.22 0.89 1.64
Breast 9 0.46 0.21 0.88 93 1.08 0.87 1.32
Endometrium 6 1.16 0.42 2.54 26 1.18 0.77 1.73
Ovary 4 1.36 0.35 3.51 7 0.81 0.32 1.68
Prostate 40 0.50 0.36 0.68 232 0.80 0.70 0.91
Kidney 16 2.92 1.66 4.75 32 2.14 1.46 3.02
Left 4 1.76 0.46 4.54 13 2.13 1.13 3.65
Right 10 3.44 0.89 8.89 10 1.70 0.81 3.13
Bladder 17 0.95 0.55 1.52 87 1.64 1.31 2.02
Melanoma 4 0.42 0.11 1.09 25 0.74 0.48 1.09
Skin SCC 27 1.55 1.02 2.26 58 1.45 1.10 1.88
Nervous system 9 1.52 0.69 2.89 14 0.85 0.46 1.43
Thyroid 5 4.13 1.30 9.70 9 2.13 0.97 4.07
Endocrine 7 2.25 0.89 4.65 22 1.46 0.91 2.21
NHL 14 1.36 0.74 2.29 41 1.58 1.14 2.15
Myeloma 4 0.89 0.23 2.30 12 1.19 0.61 2.08
Leukemia 3 0.33 0.06 0.98 21 0.99 0.61 1.51
All 297 1.04 0.92 1.16 1012 1.19 1.12 1.27
Note: Bolding shows that the 95% CI does not overlap with 1.00. 
Abbreviations: N, patient number; SIR, standardized incidence ratio; 95% CI, 95% confidence interval; SPC, second primary cancer; UAT, upper aerodigestive tract; CRC, 
colorectal cancer; HCC, hepatocellular carcinoma; NHL, non-Hodgkin lymphoma.
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Ampulla of Vater cancer was included as part of the 
above bile duct cancer. When it was considered separately, 
the SIR for pancreatic cancer was increased as SPC to 4.27 
(N=7, 95% CI 1.69–2.93). Ampulla of Vater cancer as 
SPC was associated with small intestinal (SIR 8.59, N=3, 
95% CI 1.62–25.42) and breast cancers (1.95, 24, 
1.25–2.90).
Discussion
The incidence in hepatobiliary cancers is low in Northern 
Europe compared to the high-risk areas in the world, most 
likely due to the lower level of risk factors.1,25 In Sweden, 
somewhat over 60% of the HCC patients had an underlying 
liver disease, of which 48% was HCV and 41% alcohol; 
median survival was 1.2 years.25 In the interpretation of the 
Table 3 Risks of SPCs After Gallbladder Cancer and Those of Gallbladder Cancer as SPC
Cancer Site SPC After Gallbladder Cancer Gallbladder Cancer as SPC
N SIR 95% CI N SIR 95% CI
UAT 1 0.34 0 1.94 6 0.86 0.31 1.89
Esophagus 1 0.65 0 3.72 0
Stomach 7 1.38 0.55 2.86 6 0.86 0.31 1.88
Small intestine 3 3.6 0.68 10.6 6 3.64 1.31 7.98
CRC 19 0.82 0.50 1.29 44 0.85 0.61 1.14
HCC 6 2.88 1.04 6.31 8 4.38 1.87 8.67
Bile ducts 6 5.05 1.82 11.06 2 1.71 0.16 6.27
Pancreas 4 0.70 0.18 1.80 9 1.91 0.87 3.65
Lung 7 0.49 0.19 1.01 9 0.56 0.25 1.07
Breast 14 0.56 0.30 0.94 76 0.83 0.66 1.04
Endometrium 6 0.85 0.31 1.87 27 1.11 0.73 1.62
Ovary 7 1.71 0.68 3.54 9 0.93 0.42 1.78
Prostate 15 0.78 0.44 1.30 39 0.61 0.44 0.84
Kidney 9 3.04 1.38 5.80 4 0.56 0.15 1.46
Left 4 3.44 0.90 8.90 1 0.37 0 2.11
Right 4 3.44 0.89 8.89 2 0.76 0.07 2.79
Bladder 5 0.7 0.22 1.65 16 0.89 0.51 1.45
Melanoma 4 0.79 0.21 2.05 14 0.89 0.48 1.49
Skin SCC 6 0.59 0.21 1.29 19 0.97 0.59 1.52
Nervous system 2 0.54 0.05 1.99 7 0.75 0.30 1.56
Thyroid 1 1.10 0 6.32 0
Endocrine 1 0.41 0 2.33 9 0.86 0.39 1.65
NHL 1 0.17 0 0.98 10 0.79 0.38 1.46
Myeloma 0 2 0.39 0.04 1.45
Leukemia 4 0.80 0.21 2.07 11 1.12 0.55 2.01
All 143 0.88 0.75 1.04 351 0.86 0.77 0.95
Note: Bolding shows that the 95% CI does not overlap with 1.00. 
Abbreviations: N, patient number; SIR, standardized incidence ratio; 95% CI, 95% confidence interval; SPC, second primary cancer; UAT, upper aerodigestive tract; CRC, 
colorectal cancer; HCC, hepatocellular carcinoma; NHL, non-Hodgkin lymphoma.
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present results, we need to consider survival differences of 
these cancers, and as hepatobiliary cancers have poor survival, 
we observed far more cases of these cancers as SPCs compared 
to other cancers following hepatobiliary cancers; this, in turn, is 
related to the statistical power for finding an association. We 
observed decreased risks for some SPCs, for breast cancer only 
as SPC and for prostate cancer as FPC and SPC. The likely 
reason is the reporting bias of SPCs after fatal or old age 
FPCs.20,26 The fact that for breast cancer it was observed 
only as a SPC shows one of the advantages of the bidirectional 
analysis.
The present results with increased risks of HCC after UAT, 
esophageal, kidney and bladder cancers suggest a role for the 
shared risk factors of alcohol consumption and smoking.7 
Table 4 Risks of SPCs After Bile Duct Cancer and That of Bile Ductal Cancer as SPC
Cancer Site SPC After Bile Duct Cancer Bile Duct Cancer as SPC
N SIR 95% CI N SIR 95% CI
UAT 2 0.58 0.05 2.13 11 1.37 0.68 2.46
Esophagus 0 1 0.55 0 3.12
Stomach 6 1.22 0.44 2.67 2 0.30 0.03 1.11
Small intestine 3 3.67 0.69 10.9 6 3.73 1.34 8.17
CRC 19 0.84 0.51 1.32 61 1.20 0.92 1.54
HCC 4 1.84 0.48 4.77 2 1.13 0.11 4.16
Gallbladder 2 1.71 0.16 6.27 6 5.05 1.82 11.1
Pancreas 14 2.80 1.53 4.71 8 2.09 0.89 4.13
Lung 9 0.59 0.27 1.13 9 0.58 0.26 1.10
Breast 15 0.93 0.52 1.54 80 1.25 0.99 1.55
Endometrium 2 0.46 0.04 1.68 21 1.25 0.77 1.91
Ovary 4 1.66 0.43 4.30 2 0.32 0.03 1.18
Prostate 27 0.70 0.46 1.02 74 0.68 0.53 0.85
Kidney 6 2.03 0.73 4.45 7 1.01 0.40 2.09
Left 5 4.09 1.29 9.61 3 1.07 0.20 3.16
Right 1 0.83 0 4.74 3 1.10 0.21 3.27
Bladder 3 0.32 0.06 0.95 27 1.19 0.78 1.73
Melanoma 3 0.54 0.10 1.61 10 0.59 0.28 1.09
Skin SCC 6 0.55 0.20 1.20 23 1.07 0.68 1.61
Nervous system 2 0.6 0.06 2.21 5 0.60 0.19 1.41
Thyroid 2 2.72 0.26 10.0 1 0.44 0 2.51
Endocrine 1 0.50 0 2.89 8 0.93 0.40 1.84
NHL 3 0.52 0.10 1.53 14 1.13 0.62 1.90
Myeloma 0 5 1.05 0.33 2.48
Leukemia 4 0.78 0.20 2.01 13 1.29 0.68 2.21
All 147 0.88 0.75 1.04 420 1.01 0.92 1.12
Note: Bolding shows that the 95% CI does not overlap with 1.00. 
Abbreviations: N, patient number; SIR, standardized incidence ratio; 95% CI, 95% confidence interval; SPC, second primary cancer; UAT, upper aerodigestive tract; CRC, 
colorectal cancer; HCC, hepatocellular carcinoma; NHL, non-Hodgkin lymphoma.
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HCV is also a risk factor for non-Hodgkin lymphoma, which is 
in-line with the increased risk of HCC after non-Hodgkin 
lymphoma. The vastly increased risk of HCC after autoim-
mune diseases, such as autoimmune hepatitis, and a moderate 
increase in immunosuppressed patients point to the role of 
immune dysfunction in HCC susceptibility.14,15,27 Skin SCC, 
non-Hodgkin lymphoma and upper aerodigestive tract cancer 
(including lip and mouth cancers) are hallmark cancers 
increased in immunosuppressed patients; although kidney 
and thyroid cancers are not among the hallmark cancers, they 
are also increased in immunocompromised individuals.28–30 
Thus, it is likely that immune dysfunction could have contrib-
uted to the increased risks of skin SCC, non-Hodgkin lym-
phoma (together with HCV), upper aerodigestive cancer (with 
alcohol and smoking), kidney cancer and thyroid cancer and to 
mutual association between hepatobiliary sites (together with 
surveillance bias). Surveillance bias may potentially contribute 
to the increase in many SPCs, particularly those in close 
anatomic proximity. Some studies apply lag time between 
diagnoses of FPC and SPC to reduce the influence of surveil-
lance. However, as in the Swedish Cancer Registry, practically 
all cancer diagnoses are histologically verified, lag time would 
also reduce true cancers and cause another type of bias.31
However, we should be careful not to dismiss associations 
merely because of anatomic proximity, which in the case of 
hepatobiliary cancers involve, in addition, the pancreas, duo-
denum (small intestine) and even kidneys through the perito-
neum. In the case of hepatobiliary cancers, HCC and 
gallbladder cancers associated with each other as FPC and 
SPC, and bile duct cancer associated with gallbladder cancer 
as SPC; yet no associations were observed between HCC and 
bile duct cancer. Whether this is due to the fact that the 
gallbladder is a clear anatomic entity is not known. Cancer 
cells are known to be able to spread to nearby organs through 
genetically modified clones or to exert epigenetic suppression. 
Such bystander effects of “field cancerization” or “cell compe-
tition” are known in many organ systems including the liver, 
gastro-intestinal and urothelial tracts.2,32–34 Another mechan-
ism may be local immune suppression of antitumor immune 
response by activation of FOXP3+ regulatory T cells, M2 
macrophages, CD2 dendritic cells and myeloid-derived sup-
pressor cells.35,36 The suppressive environment may extend to 
nearby organs and prevail over a period of time.37,38
Associations of hepatobiliary cancers with small intestinal 
and pancreatic cancers do not seem to be explainable by known 
environmental risk factors. For small intestinal cancer, high 
unidirectional associations were observed with gallbladder and 
biliary tract cancers but also with HCC. Biliary tract and 
gallbladder cancers manifest in HNPCC among carriers of 
the MHL1 mutations, which are the only mismatch repair 
gene mutations predisposing also to small intestinal and pan-
creatic cancers.16 Thus, HNPCC syndrome may explain the 
observed associations of these hepatobiliary cancers with small 
intestinal and pancreatic cancers. Although for the latter, the 
anatomic proximity to the bile duct may lead to surveillance 
bias, as suggested by the high risk of the cancers of the ampulla 
of Vater after pancreatic cancer (for high-grade tumors, histo-
logical distinction between the two may be critical). Although 
colorectal and endometrial cancers are hallmark cancers of 
HNPCC, they are caused also by mismatch genes other than 
MHL1, which may be the reason for their lacking association 
with hepatobiliary cancers.16
Bidirectional associations of HCC with kidney and thyroid 
cancers may have many explanations, in addition to the 
immune disturbance, discussed above. For kidney cancer, 
these include metabolic disturbances, and kidney cancer and 
HCC show the highest cancer risks in type 2 diabetes 
patients.39 Thyroid autoimmune diseases are the most common 
type of autoimmune diseases in Sweden, accounting for over 
10% of all such diseases.40 Hashimoto disease/hypothyroidism 
is the most common thyroid autoimmune disease and it is 
associated with a high risk of HCC;12 however, whether thyr-
oid autoimmunity is a precursor of thyroid cancer is somewhat 
disputed.41,42 Thus there may yet be other reasons; liver cancer 
is marginally increased in families of patients with non- 
medullary thyroid cancer but no associated genes have been 
identified.43,44
The major limitation of the study is the scarcity of data, 
particularly on rare cancers. The consequence is the generally 
low precision (wide CIs) of the risk estimates, which warrant 
caution in conclusions.24 Among hepatobiliary cancers, the 
definition of SPC may not define an independent primary but 
may be metastasis from another hepatobiliary site.45 We had no 
data on the possible risk factors, such as viral infections, or on 
personal habits, such as smoking or alcohol consumption. 
Finally, we have no data on how well SPCs are reported after 
cancers of poor survival, such as hepatobiliary cancers. 
Although international comparisons suggest that the reporting 
is high in Sweden, the present results on breast and prostate 
cancers with risks below 1.00 may indicate incomplete 
reporting.20,46 The consequence of general underreporting 
would be underestimation of risks overall. Our foremost 
strength is having access to high-level cancer registry data. 
The bidirectional design is another strength both in helping to 
interpret the associations and to reduce chance findings. 
Chance findings need to be kept in mind with these kinds of 
Clinical Epidemiology 2021:13                                                                                                      https://doi.org/10.2147/CLEP.S318737                                                                                                                                                                                                                       
DovePress                                                                                                                         
689
Dovepress                                                                                                                                                           Zheng et al





























































studies with numerous comparisons. In the above discussion, 
biological plausibility was sought to guard against chance 
findings.
In conclusion, we showed associations of HCC with 
cancers of the UAT, esophageal, kidney and bladder 
cancers and non-Hodgkin lymphoma, most likely 
explained by shared environmental risk factors. Another 
group of associated cancers were skin SCC, kidney and 
thyroid cancers and also non-Hodgkin lymphoma for 
which immune disturbance may be a contributing 
mechanism. For the rare gallbladder and bile duct can-
cers, associations with small intestinal and pancreatic 
cancers suggest genetic causation through mutations in 
the mismatch repair gene MLH1.16 HNPCC is increas-
ingly recognized as an important germline risk factor for 
many cancers, which may be diagnosed as FPCs or 
SPCs. Detection of mutations in the MLH1 gene should 
alert the clinician about the rare syndromic cancers of 
the small intestine, gallbladder and bile ducts.
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